Opthea (OPT) Competitors $3.41 +0.23 (+7.23%) As of 07/14/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPT vs. BLTE, CNTA, VCEL, IRON, HRMY, IDYA, CGON, ARQT, SRPT, and OCULShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), Disc Medicine (IRON), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), CG Oncology (CGON), Arcutis Biotherapeutics (ARQT), Sarepta Therapeutics (SRPT), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Its Competitors Belite Bio Centessa Pharmaceuticals Vericel Disc Medicine Harmony Biosciences IDEAYA Biosciences CG Oncology Arcutis Biotherapeutics Sarepta Therapeutics Ocular Therapeutix Opthea (NASDAQ:OPT) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Do insiders & institutionals hold more shares of OPT or BLTE? 56.0% of Opthea shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 3.2% of Opthea shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable valuation and earnings, OPT or BLTE? Belite Bio has lower revenue, but higher earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$120K4,373.61-$220.24MN/AN/ABelite BioN/AN/A-$36.14M-$1.36-46.56 Does the media prefer OPT or BLTE? In the previous week, Belite Bio had 12 more articles in the media than Opthea. MarketBeat recorded 13 mentions for Belite Bio and 1 mentions for Opthea. Opthea's average media sentiment score of 1.87 beat Belite Bio's score of 0.52 indicating that Opthea is being referred to more favorably in the media. Company Overall Sentiment Opthea Very Positive Belite Bio Positive Which has more volatility and risk, OPT or BLTE? Opthea has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.5, indicating that its share price is 250% less volatile than the S&P 500. Do analysts prefer OPT or BLTE? Opthea currently has a consensus target price of $1.33, indicating a potential downside of 60.90%. Belite Bio has a consensus target price of $96.67, indicating a potential upside of 52.66%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts plainly believe Belite Bio is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is OPT or BLTE more profitable? Opthea's return on equity of 0.00% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Belite Bio N/A -32.07%-30.91% SummaryOpthea beats Belite Bio on 7 of the 13 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.84M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.2228.5419.58Price / Sales4,373.61299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book-6.097.568.145.54Net Income-$220.24M-$55.11M$3.24B$257.73M7 Day PerformanceN/A3.81%0.18%-0.08%1 Month PerformanceN/A11.60%5.96%8.09%1 Year Performance60.09%-2.11%26.24%13.02% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea0.3789 of 5 stars$3.41+7.2%$1.33-60.9%+63.2%$524.84M$120K0.008Gap UpBLTEBelite Bio1.9899 of 5 stars$63.58+0.6%$96.67+52.0%+29.2%$2.02BN/A-46.7510High Trading VolumeCNTACentessa Pharmaceuticals3.1598 of 5 stars$15.13+4.9%$27.89+84.3%+58.1%$2.02B$15M-8.36200High Trading VolumeVCELVericel3.6933 of 5 stars$39.82-0.3%$61.14+53.5%-25.6%$2.00B$238.54M1,327.78300News CoveragePositive NewsIRONDisc Medicine3.2038 of 5 stars$57.74+1.5%$96.70+67.5%+14.3%$2.00BN/A-14.7330Insider TradeHRMYHarmony Biosciences4.8358 of 5 stars$34.71+2.1%$51.33+47.9%+2.4%$1.99B$714.73M13.25200News CoveragePositive NewsIDYAIDEAYA Biosciences3.5609 of 5 stars$22.58+0.4%$47.55+110.6%-48.2%$1.98B$7M-6.2980CGONCG Oncology2.5901 of 5 stars$25.90-3.1%$56.80+119.3%-31.9%$1.97B$1.14M-17.1561News CoveragePositive NewsGap UpARQTArcutis Biotherapeutics1.2759 of 5 stars$15.90+5.9%$18.80+18.2%+43.0%$1.90B$196.54M-15.29150Insider TradeSRPTSarepta Therapeutics4.7301 of 5 stars$19.23+5.8%$58.54+204.4%-88.1%$1.89B$2.23B-7.151,372Trending NewsHigh Trading VolumeOCULOcular Therapeutix3.8921 of 5 stars$11.27+2.2%$17.33+53.8%+31.6%$1.80B$63.72M-9.80230 Related Companies and Tools Related Companies BLTE Alternatives CNTA Alternatives VCEL Alternatives IRON Alternatives HRMY Alternatives IDYA Alternatives CGON Alternatives ARQT Alternatives SRPT Alternatives OCUL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
